Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHINOOK
2023-506614-40-00Phase 4Authorised
- Sponsor
- AstraZeneca
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 4, randomised, double-blind trial in eosinophilic asthma (EA) comparing Benralizumab with Placebo (2 arms). Primary endpoints: Change in submucosal eosinophil numbers and Change in airway wall area percentage. Planned start Mar 2024; status: authorised.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2023-506614-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506614-40-00.